Ola Soderquist - 19 Nov 2021 Form 4 Insider Report for BIOXYTRAN, INC (BIXT)

Reporting relationship: CFO, 10%+ Owner
Issuer ticker: BIXT
Reported as of: 19 Nov 2021
Net transaction value: -$403,165
SEC form: 4
Accepted by SEC: 18 Jan 2022, 13:02:15 UTC
Prior SEC filing: 07 Jun 2021
Next SEC filing: 28 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Ola Soderquist

Key filing fact

Ola Soderquist filed Form 4 for BIOXYTRAN, INC (BIXT) on 18 Jan 2022.

Key facts

This page summarizes Ola Soderquist's Form 4 filing for BIOXYTRAN, INC (BIXT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Jan 2022, 13:02.

Change

Previous filing in this sequence was filed on 07 Jun 2021.
Current net transaction value: -$403,165.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIXT transaction

Common

Gift

Transaction value: $441,847
Shares: -3,201,788
Change %: -12%
Price: $0.1380
Shares after: 23,337,088
Date: 19 Nov 2021
Ownership: Direct
Footnotes: F1

BIXT transaction

Common

Award

Transaction value: $2,681
Shares: +1,340,749
Change %
Price: $0.002000^*
Shares after: 1,340,749
Date: 03 Dec 2021
Ownership: by NDPD Pharma, Inc.

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIXT transaction Derivative

Warrants

Award

Transaction value: $36,000
Shares: +100,000
Change %
Price: $0.3600
Shares after: 100,000
Date: 02 May 2021
Ownership: by NDPD Pharma, Inc.
Underlying class: Common
Underlying amount: 100,000
Exercise price: $2.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares returned to Company's treasury

Footnote F2

The warrant agreement includes provisions for dilutive issuance and cash-less exercise

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .